君實生物(01877.HK)腫瘤免疫治療藥物獲Coherus行使美加開發權
君實生物(01877.HK)公佈,有關與Coherus訂立的許可與商業化協議,Coherus已於昨日(10日)啓動行使JS006選擇權的程序,以獲得許可在美國和加拿大內開發JS006或含有JS006的任何產品用於治療或預防人類疾病。
Coherus將向公司一次性支付3,500萬美元執行費,款項不可退回;在達到規定的裏程碑事件後,Coherus將向公司支付累計不超過2.55億美元的裏程碑款,外加任何包含JS006產品在Coherus區域內年銷售淨額18%的銷售分成。預計交易將在適用法律要求的政府手續完畢後完成。
JS006是公司自主研發的特異性抗人TIGIT的重組人源化單克隆抗體注射液。公司認爲,行使JS006選擇權將進一步鞏固公司與Coherus在腫瘤免疫治療領域的戰略合作關係,加快JS006在海外的臨牀開發和市場開拓,雙方正計劃在北美地區開展JS006與特瑞普利單抗聯合治療的後期臨牀試驗,評估JS006和特瑞普利單抗聯合治療的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.